BNP-7787 is primarily investigated for its protective effects against chemotherapy-induced toxicities, particularly in cancer treatment regimens involving platinum-based drugs like cisplatin. It helps reduce nephrotoxicity and neurotoxicity—common side effects of cisplatin—without interfering with the drug’s antitumor efficacy. This makes it a promising adjunct in oncology, improving patient tolerance to chemotherapy and potentially allowing for higher or more sustained dosing. Its mechanism involves scavenging reactive toxic metabolites and protecting healthy cells from oxidative damage. BNP-7787 has been explored in clinical trials for use in lung and other solid tumors, aiming to enhance the safety and effectiveness of standard chemotherapy protocols.